Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Alzheimer's Disease: Learning the Lessons Of The Past To Prepare For The Future

This article was originally published in Scrip

Executive Summary

Alzheimer's disease is the most common cause of dementia among the elderly, accounting for between 60% and 80% of cases in the US, Japan, and five major EU markets (France, Germany, Italy, Spain, and the UK). Despite decades of heavy investment in research, effective treatments for this cognitive disease are still few and AD has become a graveyard for a lot of promising drugs and billions of R&D dollars.


Related Content

Lilly Stays Committed To Alzheimer's, Including Amyloid Hypothesis, Despite Many Failures
A $63m VC Round Takes E-Scape Into Clinic With Alzheimer's, Parkinson's Drugs
Alzheimer’s Update: Amyloid Hypothesis Lives On At Biogen, Lilly, Merck, Pfizer, Roche
Merck's Promising Early Alzheimer's Data Can't Quell Efficacy Concerns
TauRx’s Data Massage Can't Work Out The Kinks Of Failed LMTX Study
Full Monty On Pfizer’s Failed 5-HT6 Alzheimer’s Drug Leaves Hope For Class





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts